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Asthma prevalence in adults: good
news?
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Time trends in asthma prevalence may have levelled off
F
ew diseases have a relation to age
which is as fascinating and complex
as for asthma. It is a chronic but not
necessarily lifelong condition. The inci-
dence of asthma and wheezing illness
peaks in very early childhood, but new
incident cases occur throughout life.1–4 In
many affected subjects, particularly chil-
dren, it disappears after some time.2–4
However, in a substantial proportion of
cases which have apparently lost the
disease it will come back, often after
many years.3 4 Another intriguing feature
is that the sex ratio changes with age.
Most studies show that boys are affected
more often by wheezing illnesses than
girls, but this sex ratio usually reverses
during or shortly after puberty, partly
due to a higher incidence in females.5–9
Most studies investigating the rela-
tionship between age and asthma have
been performed in infants and children
and, in fact, different age related phe-
notypes in childhood have been des-
cribed which seem to have distinct
causes and consequences.2 10 Informa-
tion on the relation to age in adults is
scarce and has often been based on
routine data or cross sectional studies.1 6
In this issue of Thorax Chinn and
colleagues report the findings of phase
II of the European Community Res-
piratory Health Survey (ECRHS) which
involved following more than 11 000
randomly selected adults (participants
in ECRHS phase I stage 2 at which time
they were aged 20–44 years) for a period
of 5–11 years.11 The investigators used
the same standardised questionnaires at
the start and end of the observation
period, asking about the occurrence and
severity of respiratory symptoms in the
12 months before the survey. The study
is unique because of its international
approach which included 29 study
centres from 14 countries. Consistency
of findings across countries argues
strongly for the validity of the results.
Nevertheless, there are several meth-
odological issues that should be consid-
ered before accepting the findings as
valid. In particular, measuring asthma
in populations is no easy task.12 There is
no single simple instrument by which
cases can be identified. Instead, there is
a whole battery of different measures,
all of which have advantages and dis-
advantages. Chinn et al11 report data col-
lected by standardised symptom based
questionnaires which are considered to
be the standard method for measuring
the prevalence of asthma in epidemiolo-
gical studies.12 However, since these do
not measure the prevalence of asthma
in individuals with complete accuracy,
changes within individuals between
repeated surveys may reflect measure-
ment error rather than genuine changes
in morbidity. Chinn et al therefore report
the ‘‘net change’’ in symptom status for
each centre rather than reporting sepa-
rately the rate at which previously dis-
ease free subjects became symptomatic
(incidence) and the rate at which pre-
viously diseased subjects became asymp-
tomatic (remission). While this approach
is perhaps regrettable from a clinical
point of view, it is methodologically valid
and provides findings that are of con-
siderable interest.
The study showed no increase in the
12 month period prevalence of wheeze
and more severe asthma symptoms
during the follow up period which aver-
aged about 8 years. However, there was
a significant increase in the reported
12 month period prevalence of attacks,
labelled as ‘‘asthma attacks’’, and in the
point prevalence of asthma medication
use and nasal allergies.
How can these apparently contradic-
tory patterns be reconciled? An increased
prevalence of asthma attacks andmedica-
tion use could be due to an increase in
the prevalence of severe asthma, in reco-
gnition of symptoms by patients, in diag-
nostic labelling of wheezing illness by
physicians, or in medical treatment of
the condition. Each of these, in turn, could
reflecttemporaltrends(changesovertime)
or age effects (changes with increasing
age). However, Chinn et al also measured
the prevalence of wheeze and severe
asthma symptoms and these did not
increase. It is therefore most likely that
the observed increases reflect changes in
diagnostic labelling and/or medical treat-
ment formild and/ormoderate asthma.
Although the study by Chinn et al
does not allow to disentangle potential
age and period effects, it is interesting
to review the current evidence for time
trends in asthma prevalence. An
increase in the prevalence of asthma
and allergies in the late 20th century is
generally accepted. While most studies
reported increases in the prevalence of
symptoms and diagnoses (and these
are mostly in children), these observa-
tions are supported by studies which
also included physiological markers.13
Recently, however, several studies have
suggested that this increase may have
come to an end—at least in some areas.
A study in adults over the period from
1972 to 1998 still observed increases in
the prevalence of asthma symptoms and
diagnoses which was more pronounced
among those aged less than 40 years.14
Two other studies on adults examining
time trends during the 1990s, however,
found no increase in the prevalence of
either asthma symptoms15 or bronchial
hyperresponsiveness,16 but an increase
in the prevalence of reported asthma
diagnoses. An investigation of Swiss
adolescents observed no further increase
in the prevalence of asthma symptoms
and allergic sensitisation in the late
1990s.17 Finally, Anderson et al,18 in a
large survey in the UK, actually found a
decrease in the prevalence of symptoms
of asthma, hay fever, and eczema in 12–
14 year olds between 1995 and 2002.
During the same period there was an
increase in the lifetime prevalence of
diagnoses of the three disease entities
under investigation. Robertson et al19
reported a similar reduction in the pre-
valence of asthma in children in Mel-
bourne during 1993–2004. Thus, there is
evidence from several countries that
time trends in the burden from asthma
may have levelled off—in some coun-
tries even reversed—while the rate of
reported diagnoses continued to increase.
It is important to note, however, that
these reports come mostly from high
income countries with prevalence rates
ranking among the highest in the
world.20 The global burden of asthma,
however, will be determined to a large
extent also by what happens in low
income countries. In this respect, the
upcoming results of phase III of the
International Study of Asthma and
Allergies in Childhood (ISAAC), which
has studied recent time trends in about
100 centres worldwide (including those
of Anderson et al18 and Robertson et al19),
will be of particular interest.21
If, in fact, time trends in asthma
prevalence have levelled off, it is not
clear which factors have determined this
change. It is possible that the increase
in asthma prevalence has reached a
natural plateau in English speaking
countries in which virtually all the
‘‘susceptibles’’ may have developed the
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condition. However, this speculation
would not explain the apparent decrease
in some countries. In this regard, it is
likely that improved medical treatment,
especially the use of inhaled steroids,
has contributed.16 It has been argued
that many patients do not benefit
from new treatment because their dis-
ease is not diagnosed and/or treated
adequately.22 23 In this sense, the
increased prevalence of diagnosed
asthma reported by Chinn et al, in the
absence of an increased symptom pre-
valence, could also be a reflection that
medical care of asthma patients has
changed for the better. Whatever the
explanation, the findings of Chinn et al
are in line with those of other recent
studies and may, in fact, be good news.
Thorax 2004;59:637–638.
doi: 10.1136/thx.2004.026302
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Short burst oxygen therapy for relief of
breathlessness in COPD
C M Roberts
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More evidence against the effect of short burst oxygen therapy,
but doubts remain
I
n this issue of Thorax Stevenson and
Calverley1 provide more evidence for a
lack of effect of short burst oxygen
therapy in the relief of dyspnoea follow-
ing exercise in patients with chronic
obstructive pulmonary disease (COPD).
This study follows other recent publica-
tions that appear to draw the same
conclusion. Despite this mounting evi-
dence, oxygen cylinders for ‘‘as needed’’
use are still frequently prescribed at
great cost.2 3 Oxygen used in this way
is often perceived as life saving by
patients, but can this continuing prac-
tice of short burst oxygen use for COPD
patients be justified in the light of the
emerging evidence?
Oxygen therapy for the management
of chronic COPD comes in various
forms. Long term oxygen therapy
(LTOT) prescribing has an accepted
evidence base and any patient consid-
ered for short burst treatment should
first have undergone an assessment for
LTOT. Ambulatory oxygen has been
shown to have some beneficial effect
in some patients researched in a number
of studies that demonstrate some con-
cordance. It is a continuing challenge to
the respiratory establishment, however,
that the form of oxygen most commonly
prescribed in the UK lacks such an
agreed evidence base. Short burst oxy-
gen use for the palliation of dyspnoea is
fairly widespread among patients with
severe COPD.2 Anecdotally, it is beloved
by them and often given at their request
by respiratory specialists and general
practitioners when other options have
been exhausted. When it is given there
is some evidence that it is used incon-
sistently4—either before or after exer-
cise—and that the delivery mode is non-
standardised with both face masks and
nasal cannulae being used with flow
rates set usually at 2 or 4 l/min, but
often left to the discretion of the non-
specialist or patient to determine.
This sounds like a mess that needs
sorting out and it is notable that the
initial British Thoracic Society,5 American
Thoracic Society,6 and European Res-
piratory Society7 management guidelines
for COPD had little to say on this subject.
More disappointingly, the contemporary
GOLD8 document virtually ignores short
burst oxygen and recommendations
from the 2004 NICE guideline9 consist
of rather vague statements based on
levels C and D evidence. Although this
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perceived paucity of an historical evi-
dence base has previously precluded
authoritative guidance, a number of con-
temporary studies examining the effec-
tiveness of short burst oxygen therapy
are now available for us to analyse. The
problem for the jobbing clinician is that
the available evidence has yet to be
synthesised into a whole and, practically,
this is a challenging exercise for a num-
ber of reasons evident on review of the
literature.
REVIEW OF THE EVIDENCE
Perhaps the best evidence for a positive
effect of short burst oxygen therapy in
exercise for subjects with COPD comes
from a single paper published some
years ago. Woodcock et al10 showed that
pre-dosing with oxygen for as little as
5 minutes at a rate of 4 l/min using
nasal cannulae before both a submax-
imal treadmill test and a 6 minute walk
test increased walking distance com-
pared with administered air in COPD
subjects. Dyspnoea, however, was
reduced only for the shorter treadmill
test and not for the 6 minute test. The
subjects were not severely hypoxic at
rest and real time oxygen saturation was
not measured.
Two further papers provide borderline
positive findings. Evans et al11 studied 19
hypoxic subjects with severe COPD of
mean age 65 years. Subjects undertook
three simulated step tests breathing
via a face mask, 67% oxygen, 10 l/min
compressed air, or room air with no
mask. Breathing oxygen after exercise
was associated with a shortened dys-
pnoea recovery time from 3.6 minutes
to 3.0 minutes. This study is remarkable
because it is one of only two cited in the
literature that has specifically tested the
reproducibility of patient discrimination
between oxygen and air. Little consis-
tency was found after a time interval
and the authors concluded that, despite
the reduction in recovery time observed
in the first part of the trial, the poor
reproducibility of this finding cast doubt
on the justification for short burst
therapy following exercise.
Most recently, Killen and Corris12
reported in this journal the use of short
burst oxygen given either before or after
stair climbing in 18 subjects with COPD.
Air or oxygen was delivered for 5 min-
utes at a rate of 2 l/min via a face mask
before and after ascending stairs in
subjects who desaturated on exercise.
Three combinations were provided of air
and air, air then oxygen, or oxygen then
air. Although there was no statistical
difference in dyspnoea scores between
these three groups, a statistically signifi-
cant difference in dyspnoea was seen
(visual analogue score of 7 mm) when
the oxygen subgroups were combined
compared with those breathing air.
Recovery times were not measured. The
authors suggest that this level of dys-
pnoea reduction represented a significant
benefit of short burst oxygen therapy.
One further paper which deserves
comment is that of Swinburn et al.13
This study also found a reduction in
the dyspnoea score in 12 subjects with
severe COPD at rest breathing 28%
oxygen via a face mask compared with
compressed air at the same flow rate.
Visual analogue scores reduced from
46 mm on air to 30 mm on oxygen.
The subjects were asked repeatedly
when blinded if they felt better breath-
ing air or oxygen by mask compared
with room air; compressed air helped
in 15 of 24 occasions tested and oxygen
in 22 of 24. Although often quoted as
a study supporting short burst oxy-
gen therapy, it must be noted that the
subjects were tested at rest and the
effects of exertion were not studied.
While these studies at best provide
evidence of partial benefit, there is incon-
sistency in the subject groups, exercise
performed, and outcome measures.
Moreover, there are other studies with
distinctly negative results. McKeon et al14
examined the effect of predosing with air
or oxygen at a rate of 2.5 l/min via nasal
cannulae prior to a treadmill exercise test
in 20 subjects with COPD (mean FEV1
31% predicted). No effect was observed
on the dyspnoea score during exercise.
Rhind et al15 presented similar findings in
12 subjects with COPD.
More recently, Nandi et al16 reported
the effect of both predosing for 10 min-
utes with either 28% oxygen by face
mask or compressed air at a rate of
4 l/min and also post exercise dosing
with similarly blinded gas mixtures. Six
minute walk tests were undertaken and
oxygen was found to have no benefit
compared with compressed air in terms
of relief of dyspnoea in either arm of the
study in the 34 subjects included (mean
FEV1 34% predicted). All of these sub-
jects had significant oxygen desatura-
tion. In a not dissimilar study Lewis
et al17 also used the 6 minute walk test to
study 22 patients with COPD (mean
FEV1 34% predicted) without resting
hypoxia but most of whom desaturated
on exercise. In this study the gas
mixture was administered for 5 minutes
at a flow rate of 2 l/min via nasal
cannulae. No effect was observed on
the dyspnoea score with either pre or
post dosing with oxygen compared with
compressed air.
In contrast to these at best equivo-
cal and conflicting results, there is a
clearer—although by no means per-
fect—consensus on the use of ambula-
tory oxygen therapy as an adjunct to
reducing dyspnoea and improving exer-
cise tolerance. A number of studies have
reported benefits,18–20 although not in
all subjects.21 The mechanism for this
apparent reduction in dyspnoea is pos-
tulated as the reduced work of breath-
ing when hypoxaemia is prevented or
reduced in severity.22 So why is oxygen
helpful in the ambulatory setting but
of less value following exercise? One
key element of the increased work of
breathing in patients with limited
expiratory flow is the development of
dynamic hyperinflation.
STUDY BY STEVENSON AND
CALVERLEY
It is argued by Stevenson and Calverley1
in this issue of Thorax that a reduction
in dynamic hyperinflation may hold the
key to the successful identification of
those subjects who will benefit from
oxygen and, specifically in this study,
those using it as a short burst dosing
intervention following exercise.
Stevenson and Calverley administered
oxygen at an inspired oxygen fraction
of 0.4 or air at a similar flow rate
(10 l/min) to 18 moderately severe
COPD patients (FEV1 40% predicted)
after standardised exercise. In this study
subjects exercised both ‘‘instrumented’’
in a full cardiorespiratory exercise test
breathing via a mouthpiece and ‘‘non-
instrumented’’ breathing from a face
mask. The hypothesis tested was that
oxygen administration should reduce
the work of breathing and aid resolution
of dynamic hyperinflation by reducing
tidal volume breathing and allowing
an increased expiratory time. Admini-
stration of oxygen after exercise was
associated with a reduced ventilatory
effort and more rapid resolution of
dynamic hyperinflation but no signifi-
cant reduction in dyspnoea. The find-
ings were essentially negative in that,
although observed changes occurred,
these did not produce a significant
reduction in breathlessness as measured
by a Borg scale when oxygen adminis-
tration was compared with that of air.
A significant difference in recovery
time of dyspnoea was noted, however,
between the instrumented mouthpiece
tests (11.38 (1.49) minutes) and those
when face masks alone were used (7.94
(1.12) minutes).
The study by Stevenson and Calverley
adds to the evidence that there is no
single easily measured mechanism by
which oxygen reduces dyspnoea after
exercise, and that the mechanisms
which may operate to prevent dyspnoea
when oxygen is administered during
exercise may not be the same as those
which may operate in influencing dys-
pnoea after exercise. The authors point
out that the reduced recovery time
observed in the subjects when receiving
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oxygen by face mask may reflect stimu-
lation of facial receptors that could
reduce dyspnoea perception.23 Even this
suggestion is contentious in the context
of clinical use of short burst oxygen
after exercise. The best evidence for a
positive effect of oxygen was derived
from a study using nasal cannulae
rather than masks,10 and a recent study
examining the effect of mask versus
room air breathing concluded that any
apparent benefit is an order effect of
exercise rather than a result of either
oxygen or delivery apparatus.24
CLINICAL IMPLICATIONS
The difficulty for those trying to develop
guidelines in this arena is the disparate
nature of these studies. In some the
study end points were dyspnoea and in
others exercise tolerance; the nature and
duration of exercise was different; the
inspired oxygen tensions, flow rates and
delivery systems were not standardised;
and perhaps most challenging of all
were the settings for the studies. Finally,
as clinicians we must ask practical
questions—are the study subjects
included the ones we would consider
recommending for short burst oxygen
therapy and are the study circumstances
those in which patients commonly use
this form of oxygen?
What we may deduce so far is that
short burst oxygen therapy either before
or after exercise probably does not bene-
fit the majority of patients with moder-
ately severe COPD who exercise for more
than a very short period of time. Before
comprehensive recommendations can be
made we still require specific studies to
re-evaluate the work of Swinburn13 and
Killen12 in subjects at rest and after very
short episodes of exertion set in the
circumstances of everyday living.
Thorax 2004;59:638–640.
doi: 10.1136/thx.2003.017301
Correspondence to: Dr C M Roberts,
Department of Respiratory Medicine, Whipps
Cross University Hospital, London E11 1NR;
Michael.Roberts@whippsc.nhs.uk
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Regulatory T cells and asthma and
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A better understanding of the immunology of regulation may
allow preventive or disease modifying treatment for asthma and
other respiratory diseases
M
uch is currently made of the
control of asthma in therapeutic
guidelines. Both the British
guidelines and the Global Initiative for
Asthma (GINA) define measures of
control of the disease, and recent studies
have defined strategies for control using
available anti-inflammatory and bron-
chodilator therapy such as inhaled
steroids and long acting b2 agonists.
1 2
However, currently available treatments
suppress inflammation but do not mod-
ify the underlying immunological pre-
disposition to the disease.
Asthma is widely recognised as an
inflammatory airway disease driven by
activation of Th2-type T lymphocytes in
both atopic allergic and intrinsic or non-
allergic forms.3–5 Recent advances in our
understanding of the control of the
immunological process have identified
regulatory suppressive T cells which can
prevent activation of self-reactive or
pathological T cells in autoimmune or
infectious disease models.6–8 Does this
understanding of immune regulation
hold the prospect of disease control or
even prevention for asthma?
MECHANISM OF ACTION
The interest of immunologists in
actively suppressive T cells was re-
awoken by the finding by Sakaguchi
and co-workers that depletion of
CD4+CD25+ T lymphocytes from mice
led to development of autoimmune
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pathology which could be prevented by
re-introduction of these cells.9 Such
CD4+CD25+ regulatory T cells were
active in many disease models and could
reverse established inflammatory dis-
eases such as colitis.10 These cells were
shown to arise by high affinity selection
in the thymus and are thought to form a
‘‘naturally occurring’’ regulatory popu-
lation that is an important part of
maintenance of tolerance or non-reac-
tivity of the immune system against
itself.11 12 Shevach and co-workers estab-
lished an in vitro system and showed
that CD4+CD25+ T cells failed to pro-
liferate to polyclonal or antigenic stimu-
lation in culture; furthermore, they
could suppress proliferation and cyto-
kine production by CD4+CD252 T
cells.13 This system showed that human
peripheral blood CD4+CD25+ T cells also
represent a non-proliferating suppres-
sive T cell population.14–19 The mechan-
ism of suppression by CD4+CD25+
regulatory T cells remains unclear: in
some in vivo models suppression is
dependent on the immunosuppressive
cytokines interleukin 10 (IL-10) and
transforming growth factor b (TGFb),
whereas suppressive activity in vitro is
not affected by the absence or neutrali-
sation of these factors.7 8 In vitro sup-
pression by both mouse and human
CD4+CD25+ T cells requires contact
between regulating and responding cells
and is partly dependent on negative co-
stimulatory signals including CTLA4
and PD-1.7 As CD25 is the alpha chain
of the IL-2 receptor and these cells do
not make their own IL-2, one possibility
is that regulation occurs through com-
petition for this and other T cell growth
factors as well as by competition for
‘‘space’’ in repopulation experiments in
lymphopenic mice.20 Since CD4+CD25+
T cells could regulate non-T cell depen-
dent colitis in a mouse model, such
interactions with responder T cells
cannot be the sole mode of suppression
and regulatory T cells are likely to
influence cells of the innate immune
system including dendritic cells.21 Can
CD4+CD25+ T cells inhibit activation of
Th2 cells in animal models or in vitro?
Animal models
Animal models of allergic airway sensi-
tisation have been useful in defining
potential immunological mechanisms in
asthma and allergic disease.22 However,
there are few data on CD4+CD25+ T cell
regulation of mouse Th2 airway inflam-
mation and airway hyperresponsive-
ness. When CD4+CD25+ T cells were
depleted in one model airway, inflam-
mation actually decreased.23 This may
be because CD25 is also a marker of
recently activated T cells or memory
effector cells, so both regulators and
effectors had been removed. However,
co-transfer of ex vivo expanded
CD4+CD25+ ovalbumin specific T cells
together with Th2 cells had no effect
on subsequent inhaled ovalbumin chal-
lenge in another mouse model,24 and
ovalbumin specific airway CD4+CD25+
T cells in another complex double trans-
genic model reduced airway inflamma-
tion but not airway hyperresponsiveness
in response to inhaled challenge.25
In vitro experiments
Human peripheral blood CD4+CD25+
T cells were shown to be suppressive in
allergen stimulated cultures.26–28 We
recently compared such suppressive
activity in allergen stimulated in
vitro cultures of CD4+CD252 and
CD4+CD25+ T cells from non-atopic
and atopic volunteers. CD4+CD25+ T
cells suppressed proliferation and cyto-
kine production by CD4+CD252 from
non-atopic subjects almost completely,
but this suppressive activity was signifi-
cantly reduced in cultures from atopic
volunteers, particularly when blood was
taken from hay fever sufferers during
the height of the pollen season.28
Interestingly, removal of CD4+CD25+ T
cells from peripheral blood of non-
atopic individuals revealed proliferation
and Th2 cytokine production to allergen
stimulation which was similar to that
from atopic volunteers. These data led to
the suggestion that Th2 responses to
allergen in non-atopic subjects may be
actively suppressed by CD4+CD25+ T
cells, and that this regulation is either
deficient in atopic subjects or overcome
by allergen exposure. Clearly, further
work is required to determine whether
such regulatory cells occur in the airway
or are reduced in asthma.
Although CD4+CD25+ regulatory T
cells have been isolated from lung tissue
around lung cancers,29 phenotypic iden-
tification of regulatory T cells is ham-
pered by the lack of a specific cell
marker. One important advance in
understanding the regulatory function
of these cells came from studies of a rare
human immunodefiency (IPEX) which
results in autoimmune and allergic
disease and its murine counterpart, the
‘‘scurfy’’ mouse strain: both were shown
to result from mutation of a tran-
scription factor termed FoxP3.30 31
Furthermore, in elegant experiments
FoxP3 knockout mice were shown to
lack CD4+CD25+ regulatory T cells,
whereas ectopic expression of the tran-
scription factor by retroviral transfer
into CD4+CD252 T cells rendered these
regulatory.32–34 How FoxP3 influences
suppression is unclear, and although
we and others have confirmed relative
overexpression of mRNA for FoxP3 by
human CD4+CD25+ T cells,28 this may
not represent a specific marker for this
cell type35 nor does it appear to be active
in suppression by other regulatory T cell
subtypes. Recently, neuropilin-1 was
identified as a potential surface marker
for mouse CD4+CD25+ T cells.36
It is therefore possible that atopy (and
asthma) result from a failure to sup-
press inappropriate Th2 responses to
environmental allergens. What factors
determine the balance between regula-
tory and potentially immunopathogical
Th2 responses to allergen exposure in
the developing (or mature) immune
system? Increasing interest has focused
on the mode of activation of the innate
immune system (including airway den-
dritic cells) as a major determinant of
the type of T cell response to antigen
exposure. As well as the route, dose and
frequency of antigen exposure, co-acti-
vation of pattern recognition receptors
such as Toll-like receptors (TLR) or co-
stimulatory molecules act as important
determinants of T cell activation.37 It is
possible that relative levels of activation
of these receptors may be relevant—for
example, low dose bacterial lipopolysac-
charide (LPS) acting through TLR4
favours Th2 development38 whereas
higher doses drive Th1 development
and exposure of dendritic cells to LPS
can overcome regulation by CD4+CD25+
T cells.39 40 Similarly, the balance of co-
stimulation may be important as ICOS
co-stimulation is active in supporting
Th2 responses but can also drive devel-
opment of IL-10 producing regulatory T
cells in the mouse lung.41 Such consid-
erations may provide an immunological
basis for the hygiene hypothesis for the
increasing prevalence of asthma and
allergic disease: this may represent a
failure of development of appropriate
regulatory responses due to lack of
appropriate TLR or co-stimulator activa-
tion at the time of allergen exposure.42 It
may also underlie some of the genetic
associations of asthma as with TLR2 or
CD14 (an LPS receptor) polymorph-
isms.43 44 It is noteworthy that high
exposure to cat allergen reduces the risk
of IgE sensitisation and induces an IL-
10 predominant ‘‘modified Th2’’ res-
ponse which may represent regulation.45
However, such a protective effect of high
level allergen exposure is not reported
for house dust mite. Much more work is
required before exposure to allergen or
other factors can be manipulated to
prevent allergic sensitisation.
CLINICAL IMPLICATIONS
How might regulatory T cells be
manipulated or induced for treatment
or prevention of asthma? Although
CD4+CD25+ T cells do not proliferate
in vitro in many systems, it has recently
been shown that human cells can be
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expanded in response to antigen46 and
CD4+CD25+ T cells do proliferate upon
in vivo transfer to mice.47 It is suggested
that suppression by CD4+CD25+ T cells
is not antigen specific once these cells
are activated, and it might be feasible
to transfer cells expanded ex vivo.
However, such cell therapy would be
complex and potentially hazardous.
Another approach is to induce a regula-
tory population in vivo. Such ‘‘adaptive’’
regulatory T cells have been described in
vivo in mice and in vitro in mice and
humans and include a range of subtypes
that are distinct from the ‘‘naturally
occurring’’ CD4+CD25+ T cells.12 For
example, IL-10 producing regulatory T
cells were derived in vitro from both
human and mouse T cells by activation
in the presence of dexamethasone and
vitamin D3 (which inhibit development
of Th2 and Th1 cells, respectively).48 This
raises the possibility of inducing similar
cells by in vivo allergen exposure in the
face of immunosuppressive agents. We
recently showed that in vitro exposure
of CD4+CD25+ T cells to corticosteroids
increased their suppressive activity in
subsequent allergen stimulated cultures
through increased IL-10 production.49
IL-10 producing regulatory T cell clones
were produced by activation in the
presence of IL-10: these Tr1 cells pre-
vented IgE and Th2 expansion in a
mouse model of allergic airways disease
but also produced both IL-5 and inter-
feron c.50 51 Animal models of tolerance
involving nasal or oral delivery of
protein or peptide also induce regula-
tory T cell populations—either IL-10
producing T cells or Th3 cells making
TGFb.52 53 For many years allergen injec-
tion immunotherapy has been used to
control allergic diseases including rhini-
tis and seasonal asthma,54 55 and this
treatment produces long lasting clinical
effects and a reduction in Th2 responses
to allergen exposure. Allergen immu-
notherapy also induces a predominant
IL-10 response to allergen, and this
may be associated with development
of regulatory T cells which were
CD4+CD25+.56 57 Whether this pheno-
type relates to CD4+CD25+ regulatory T
cells or represents activation by allergen
remains to be determined, although no
difference was found in the suppressive
activity of peripheral blood CD4+CD25+
T cells from hay fever patients who had
or had not been treated with immu-
notherapy.58 Allergen immunotherapy is
not used for asthma treatment in the
UK because of the risk of anaphylaxis,59
but a number of modifications may
allow its development for asthma. One
approach is to break the allergen into
short peptides which retain T cell
reactivity but which no longer crosslink
IgE (so it will not trigger anaphylaxis).60
This approach shows some efficacy in
reducing airway hyperresponsiveness
and reduced peripheral blood Th2
responses to allergen, again with an
increase in IL-10 production.61 62 We
recently showed that reduced CD4+ T
cell responses to cat allergen following
peptide therapy were not associated
with changes in suppression by blood
CD4+CD25+ T cells,63 so this type of
immunotherapy may induce other reg-
ulatory T cell subtypes (or work in
another fashion). Other approaches are
a combination of immunotherapy with
adjuvants such as CpG oligonucleotides
(which activate TLR9) or mycobacterial
products.64 65 Clearly, it will be impor-
tant to establish both safety and bystan-
der suppression of other allergens or
antigens before these approaches can be
used clinically. However, it is interesting
that allergen immunotherapy reduced
the development of both new allergen
sensitisation and of asthma in trials in
children with allergic rhinitis, which
suggests that immune modulation may
hold the potential to prevent asthma.66 67
CONCLUSIONS
Current data support the suggestion
that regulatory T cells may be important
in preventing allergic sensitisation in
non-allergic individuals. If the balance
between regulation and activation of
Th2 T cells can be manipulated, this
holds great promise for treatment and
prevention of asthma. Regulatory T cells
may also be important for a number of
other lung diseases: CD4+CD25+ T cells
isolated from lung tissue around lung
cancers suppressed anti-tumour res-
ponses and temporary inactivation of
such suppression may be useful for
treatment.29 It is also possible that air-
way inflammation in chronic obstruc-
tive pulmonary disease results from a
failure to suppress T cell responses to
host antigens revealed or altered by
smoking or infection. Understanding
and manipulation of immune regulation
will form a key part in the development
of new treatments in coming years.
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Antiviral agents and corticosteroids in
the treatment of severe acute
respiratory syndrome (SARS)
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Systematic evaluation of treatment modalities for SARS is still
needed
T
he epidemic of severe acute respira-
tory syndrome (SARS) of 2003
caught the medical profession by
surprise. The accumulated global total
number of cases was 8098 with 774
deaths, a case-fatality ratio of 9.6%.1
Although the novel coronavirus (SARS-
CoV) was discovered within weeks,2
treatment was inevitably empirical as
controlled clinical trials were not possi-
ble during the epidemic of this new and
serious illness. Many antiviral and
immunomodulatory drugs, as well as
other treatments such as convalescent
patient plasma and traditional Chinese
medicines, have been tried. Ribavirin
and corticosteroids are by far the most
widely used treatments for SARS. In the
later phase of the epidemic lopinavir
and ritonavir in combination were also
used in Hong Kong.
ANTIVIRAL AGENTS
Ribavirin
Ribavirin is used extensively for the
treatment of SARS and was given to
over 90% of patients in Hong Kong. It is
a nucleoside analogue that has activity
against a number of DNA and RNA
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viruses in vitro.3 The mechanism of
action of ribavirin has been studied for
decades and is still under active debate.4
In early March 2003, before the isolation
of the SARS-CoV, many experts believed
that the mysterious severe illness was
due to an unknown virus and ribavirin
was empirically given because of its
broad spectrum antiviral activity. Fur-
thermore, corticosteroids were increas-
ingly prescribed for the treatment of
SARS and some believed that such
treatment would be dangerous if not
covered with an antiviral agent. The
published reports on the effectiveness of
ribavirin were mostly retrospective case
series with intrinsic methodological
issues and it is difficult to draw conclu-
sions. The major side effect of ribavirin
is anaemia which occurs in 27–59% of
patients.5–9 Anaemia reduces oxygen
transport and potentiates the existing
problem of oxygenation and tissue
hypoxia. Other significant side effects
include raised transaminases and
bradycardia,5 as well as hypocalcaemia,
hypomagnesaemia, and risk of terato-
genicity.10 In a detailed study on the
clinical course and viral load, Peiris et al11
reported that 14 patients given a stan-
dard regimen of ribavirin and steroids
showed a peak viral load at day 10 from
onset of illness. This study, although
involving a small number of subjects,
clearly indicated the inability of riba-
virin to clear SARS-CoV from patients
with SARS. The result of this study also
explained why patients treated with
ribavirin early in the illness were able
to infect healthcare workers when they
subsequently required endotracheal intu-
bation. The lack of in vitro activity of the
drug against SARS-CoV12–14 cast further
doubts on the usefulness of ribavirin in
SARS. The use of ribavirin in SARS has
been reviewed elsewhere.15 16
Lopinavir and ritonavir
Lopinavir and ritonavir (LPV/r) are
protease inhibitors which, in combina-
tion, have been licensed for the treat-
ment of HIV disease. Ritonavir has little
antiviral activity and its role is to inhibit
CYP3A mediated metabolism of lopina-
vir, thus increasing the serum concen-
tration of lopinavir. In the laboratory
lopinavir and ribavirin have significant
synergism in inhibiting SARS-CoV6 and,
on that basis, this combination—
together with steroids—have been used
in some centres in Hong Kong since mid
April 2003. In this retrospective study
the authors found that the 12 patients
who received early treatment with LPV/r
together with ribavirin and steroids had
significantly fewer 21 day adverse clin-
ical outcomes (acute respiratory distress
syndrome or death) than 111 historical
controls receiving ribavirin and steroids.
Other benefits of the LPV/r group
included favourable viral load profiles
(in six patients), early rise of lympho-
cyte counts, and a reduced need for
‘‘rescue’’ pulse steroid doses. Adverse
events attributable to LPV/r were mini-
mal. Similar findings were reported
in a case controlled study involving
more patients from Hong Kong.17
Randomised controlled trials are being
planned in Hong Kong to confirm these
results should SARS re-emerge.
CORTICOSTEROIDS
Corticosteroids have been used widely
to treat SARS, first in mainland China
and then in Hong Kong. The main
rationale for their use in SARS is that,
in acute viral respiratory infections,
early response cytokines such as inter-
feron gamma (IFN-c), tumour necrosis
factor, interleukin 1 (IL-1), and inter-
leukin 6 (IL-6) contribute to tissue
injury,18 19 and corticosteroid treatment
may suppress the ‘‘cytokine storm’’.20
Peiris et al hypothesised that the clinical
worsening often observed during the
second phase of illness is the result of
immunopathological damage from an
overexuberant host response.13 In a
newly published report Wong et al21
showed in 20 consecutive adults with
SARS that there was a marked increase
in the Th1 cytokine IFN-c, inflamma-
tory cytokines IL-1, IL-6, and IL-12 for
at least 2 weeks after disease onset. The
chemokine profile showed a significant
increase in IL-8, monocyte chemoatt-
tractant protein-1 (MCP-1), and IFN-c
inducible protein-10 (IP-10). Corticos-
teroids significantly reduce IL-8, MCP-1,
and IP-10 concentrations 5–8 days after
treatment. The data confirmed the Th1
cell mediated immunity and hyperin-
nate inflammatory response in SARS
through the accumulation of mono-
cytes/macrophages and neutrophils.
Another rationale for use of steroids
in SARS is the necroscopic finding of
features of acute respiratory distress
syndrome (ARDS),22 23 and there have
been reports of successful use of steroids
in the treatment of ARDS24 and septic
shock.25 In addition, systemic steroids
have been used in the treatment of some
infections with variable success.26–29 On
the other hand, the potential for corti-
costeroids to suppress the innate host
defence against SARS-CoV resulting in
increased viral replication has to be
considered. Chu et al reported an
increase in viral load in one patient
following pulse methylprednisolone
therapy.6 Increased replication of other
respiratory viruses has also been
reported following steroid therapy.26 30–32
Whereas ‘‘low dose’’ steroids at 0.5–
1.0 mg/kg/day prednisolone (or equiva-
lent) have been used in infections,
ARDS and septic shock, ‘‘pulse doses’’
at 0.5–1.0 g/day methylprednisolone
have generally not been recommended
for these conditions but were used
extensively in SARS, particularly in the
second week of illness when patients
often show acute clinical deterioration.
The efficacy of pulse steroids in SARS
remains to be determined, but it is
conceivable that higher steroid doses
will result in a higher incidence and
severity of side effects.
Published case series examining the
clinical efficacy of steroid treatment in
SARS7 9 33–40 suffer the same methodolo-
gical problems as those of ribavirin. In
addition, there is a wide variety of
steroid dosing schedules making retro-
spective analysis of steroid efficacy
exceptionally difficult. There is so far
no systematic review of the efficacy of
corticosteroid treatment in SARS based
on the numerous published studies.
Some investigators do feel that judicious
use of corticosteroids is beneficial, but
randomised controlled studies are
needed to confirm the beneficial effects
as well as to give insight into the
optimal regimen. The possible beneficial
effects, however, have to be balanced
against the significant side effects
including nosocomial infections,7 9 40 41
hyperglycaemia, hypokalaemia, hyper-
tension, and gastrointestinal haemor-
rhage.7–9 Avascular necrosis of bone
(AVN) is perhaps the most distressing
medium term side effect of steroids in
patients with SARS. Preliminary data on
a cohort of 330 adult patients from
Princess Margaret Hospital, Hong Kong
who received various doses of steroids
and in whom magnetic resonance ima-
ging was performed at an average of
7.5 months from illness onset showed
that AVN was present in 48 of them
(14.5%, (unpublished data). Of the 48,
16 (33%) had unilateral involvement of
the femoral head and 19 (40%) had
bilateral involvement of the femoral
head. Univariate analysis showed that
the total steroid dose was significantly
associated with development of AVN
(unpublished data).
CONCLUSIONS
As SARS has only recently appeared and
a limited number of patients have been
managed in different locations, it is
understandable that there has been a
lack of systematic and critical evaluation
of treatment in the form of randomised
controlled trials. Nonetheless, the enor-
mous effort that researchers put into
looking for effective treatments for
SARS is highly commended. The recent
re-emergence of SARS did not result
in secondary spread, but is nevertheless
a reminder that it could strike again.
What may be even more threatening
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is the deadly avian influenza A (H5N1)
which has repeatedly demonstrated
its ability to infect humans, and may
acquire the ability for efficient human to
human transmission in the future. It is
hoped that, when epidemics of new
disease strikes, a systematic way of
evaluating treatment modalities would
be in place to provide answers to
important questions in the shortest
possible time.
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